Hydralazine (hydrochloride)

Hydralazine is an orally bioavailable vasodilator and antihypertensive agent. It decreases DNA methylation in Jurkat cells at a concentration of 10 µM and inhibits extracellular and intracellular production of reactive oxygen species (ROS) in rat macrophages activated by phorbol 12-myristate 13-acetate (PMA, Cay-10008014) at a concentration of 100 µM. Hydralazine (100 µM) also decreases nitric oxide production and mRNA expression of inducible nitric oxide synthase (iNOS) in rat macrophages activated by LPS (Cay-19660, 19661) and interferon-gamma (IFN-gamma). It reduces contraction of rat aortic arterial strips induced by potassium and norepinephrine (Cay-16673, IC50s = 2.2 and 3.06 mM, respectively). Hydralazine (2.6 mg/kg) lowers mean arterial blood pressure (MAP) by 41.76% in conscious rats. Formulations containing hydralazine have been used in the treatment of high blood pressure and heart failure.Formal Name: 1-hydrazinyl-phthalazine, monohydrochloride. CAS Number: 304-20-1. Synonyms: 1-Hydrazinophthalazine. Molecular Formula: C8H8N4 . HCl. Formula Weight: 196.6. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: Ethanol: slightly soluble, Methanol: slightly soluble, Water: soluble. lambdamax: 211, 236 nm. SMILES: N/N=C1NN=CC2=C\1C=CC=C2.Cl. InChi Code: InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8,/h1-5H,9H2,(H,11,12),1H. InChi Key: ZUXNZUWOTSUBMN-UHFFFAOYSA-N.